Navigation Links
FDA Approves New Treatment for Type 2 Diabetes
Date:5/2/2011

SILVER SPRING, Md., May 2, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Tradjenta (linagliptin) tablets, used with diet and exercise, to improve blood glucose control in adults with Type 2 diabetes.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

People with Type 2 diabetes do not produce or respond normally to insulin, a hormone that regulates the amount of glucose in the blood. Over time, high blood glucose levels can increase the risk for serious complications, including heart disease, blindness, and nerve and kidney damage.

"This approval provides another treatment option for the millions of Americans with Type 2 diabetes," said Mary Parks, M.D., director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research. "It is effective when used alone or when added to existing treatment regimens."

Type 2 diabetes is the most common form of the disease, affecting between 90 percent and 95 percent of the 24 million people in the United States with diabetes. Tradjenta increases the level of hormones that stimulate the release of insulin after a meal by blocking the enzyme dipeptidyl peptidase-4 or DPP-4, which leads to better blood glucose control.

Tradjenta was demonstrated to be safe and effective in eight double-blind, placebo-controlled clinical studies involving about 3,800 patients with Type 2 diabetes. The studies showed improvement in blood glucose control compared with placebo.

Tradjenta has been studied as a stand-alone therapy and in combination with other Type 2 diabetes therapies including metformin, glimepiride, and pioglitazone. Tradjenta has not been studied in combination with insulin, and should not be used to treat people with Type 1 diabetes or in those who have increased ketones in their blood or urine (diabetic ketoacidosis).

Tradje
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Zytiga for Late-Stage Prostate Cancer
2. FDA Approves Updated, Clarified Indication for Use for iFuse Implant System®
3. FDA Approves Lamictal®XR™ (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
4. FDA Approves the First Vaccine to Prevent Meningococcal Disease in Infants and Toddlers
5. FDA Approves Actemra to Treat Rare Form of Juvenile Arthritis
6. FDA Approves New Medical Device for Form of Brain Cancer
7. FDA Approves the NovoTTF-100A System for the Treatment of Patients With Recurrent Glioblastoma Multiforme (GBM) Brain Tumors
8. FDA Approves Horizant To Treat Restless Legs Syndrome
9. FDA Approves New Treatment for Rare Form of Thyroid Cancer
10. FDA Approves Special Protocol Assessment for Phase 3 Trial of Polaris Groups Cancer Therapeutic, ADI-PEG 20, in the Treatment of Hepatocellular Carcinoma
11. FDA Approves Hyperopia Application for the MEL 80 Excimer Laser from Carl Zeiss Meditec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014  ConvaTec, a privately-held medical products and ... appointed Interim Chief Executive Officer of the company, effective ... Ken Berger .  "The Board of Directors of ConvaTec ... over the past three years," said Magnus Lundberg ... are confident that the company is well positioned for ...
(Date:12/22/2014)... Dec. 22, 2014  Mark Farrah Associates (MFA), ... a summary of the 2015 marketplace exchange projections ... According to a recent ASPE ... Evaluation, Department of Health and Human Services) report, ... individual medical plans through the Marketplace as of ...
(Date:12/22/2014)... 2014 TWi Biotechnology, Inc., today announced ... AC-201, TWi Biotechnology,s lead drug candidate, from The ... for patent application numbered 201180018154.8.  This ... active metabolite for treatment of type II diabetes.  ... using AC-201 for type II diabetes, and provides ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Insights into the Marketplace and Individual Market Growth 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3
... , BUDAPEST, Hungary , ... Pfizer Globally Licenses ChemAxon,s Platform For Markush Structure,Searching And Enumeration ... of cheminformatics software for the life,sciences industry has entered into ... functionality for global,development and deployment within Pfizer,s global R&D facilities. ...
... , , , ... The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) ... sclerosis (MS). In clinical trials, patients treated with Ampyra had ... (placebo). This is the first drug approved for this use. ...
Cached Medicine Technology:FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis 2
(Date:12/22/2014)... 2014 International efforts to ... epidemic are receiving further support from recent ... organizations (NGOs) and other charitable organizations. While ... emergency responders, patients and others can immediately ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... 2014 The Bob Woodruff Foundation ... invested more than $5 million in programs and ... their families. , This includes $1.3 million in ... helping with: veteran entrepreneurship; community impact; vocational training; ... severely injured veterans. , “The needs of those ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Give a ... season, the gift of health and vitality. , For ... its three top-selling anti-aging formulas in special Holiday Wellness ... rush delivery. , Each bottle contains cutting-edge, proven ... that don't work as well as we age. ...
(Date:12/22/2014)... York NY (PRWEB) December 22, 2014 ... that a federal panel of judges has granted a ... in the U.S. District Court, Eastern District of ... issued an order on December 12 to transfer over ... in 22 districts to the Louisiana court for consolidation ...
(Date:12/22/2014)... December 22, 2014 Christmas is days away, ... a fast and easy solution that will please: the ... be purchased from from $25 up to $350," says Kathy ... customer satisfaction and a wide array of skin care products ... and no expiration dates. , Gift delivery past shipping ...
Breaking Medicine News(10 mins):Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4
... separated at the time of diagnosis do not live as ... the conclusion of a new study to be published in ... peer-reviewed journal of the American Cancer Society. The authors of ... with marital separation may compromise an individual,s immune system and ...
... A new technique may help clinicians hone in on a ... cause. The study, led by principal investigator Y.C. ... the American Thoracic Society,s American Journal of Respiratory and ... of fluid in the pleural cavity, can be maddeningly difficult ...
... Pulmonary Fibrosis is not much better than a death ... is less than three years. But researchers at ... a novel gene utilizing genetic and pharmacologic strategies was ... be developed for future testing in humans. The ...
... works best , SUNDAY, Aug. 23 (HealthDay News) -- Medics ... activity when trying to save a person who,s had a ... defibrillation to restart the heart. , But studies now show ... as ordinary cardiopulmonary resuscitation, or CPR. And what,s more, those ...
... ... facility, positioning the company to support defense-related semiconductor manufacturing and development programs. , ... Cherry Hill, NJ (PRWEB) ... Arms Regulations) registered for its Cherry Hill, New Jersey manufacturing facility. ITAR regulates the ...
... root, study finds , FRIDAY, Aug. 21 (HealthDay News) -- ... before they take root in the brain. , That,s the ... rats -- assuming the findings can be applied to humans, ... of Rio Grande do Sul, Brazil, with colleagues at the ...
Cached Medicine News:Health News:Cancer patients who are separated when diagnosed have worse survival rates 2Health News:New technique can help diagnose mesothelioma 2Health News:U-M researchers discover therapeutic target that could help patients with pulmonary fibrosis 2Health News:It's Back to Basics to Save a Life 2Health News:It's Back to Basics to Save a Life 3Health News:International Micro Industries (IMI) is ITAR Registered 2Health News:Dopamine Lets Bad Experiences Linger 2Health News:Dopamine Lets Bad Experiences Linger 3
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Ethicon Endo-Surgery provides disposable handheld instruments that provide reliable, precise performance every time. Our handheld instruments come in 5mm and 10mm sizes....
... The Auto Suture™ ... inclusive of five (5) ... application in a variety ... urologic, colorectal and other ...
The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
Medicine Products: